

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

11767-032-999

APPLICATION NO.

09/623,543

APPLICANT

Bridon et al.

FILING DATE

September 5, 2000

ART UNIT

1642

U.S. PATENT DOCUMENTS

| *Examiner Initials | Document Number | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|------------------|---------------|---|---|
| | A01 5,424,286 | 06/13/95 | Eng | |
| | A02 60/037,412 | 02/05/97 | Drucker | |
| | A01 60/103,498 | 10/08/98 | Coolidge <i>et al.</i> | |
| | A04 60/132,018 | 4/30/99 | Prickett <i>et al.</i> | |
| | A05 6,284,725 B1 | 09/04/01 | Coolidge <i>et al.</i> | |
| | A06 6,451,974 B1 | 09/17/02 | Hansen | |
| | A07 6,723,530 B1 | 04/20/04 | Drucker | |
| | A08 6,767,887 B1 | 07/27/04 | Hoffman <i>et al.</i> | |
| | A09 60/152,681 | 09/07/99 | Ezrin <i>et al.</i> | |
| | A10 2003/0170250 | 09/11/03 | Ezrin <i>et al.</i> | |
| | A11 2004/0156859 | 08/12/04 | Ezrin <i>et al.</i> | |
| | A12 2004/0266673 | 12/30/04 | Bakis <i>et al.</i> | |
| | A13 2005/0065075 | 03/24/05 | Erickson <i>et al.</i> | |
| | A14 2005/0070475 | 03/31/05 | Bridon <i>et al.</i> | |
| | A15 2005/0176641 | 08/11/05 | Bakis <i>et al.</i> | |
| | A16 2005/0176643 | 08/11/05 | Bridon <i>et al.</i> | |
| | A17 2006/0058235 | 03/16/06 | Bridon <i>et al.</i> | |
| | A18 2006/0135426 | 06/22/06 | Bridon <i>et al.</i> | |
| | A19 2006/0135428 | 06/22/06 | Bridon <i>et al.</i> | |
| | A20 2006/0217304 | 09/28/06 | Bridon <i>et al.</i> | |
| | A21 2006/0241019 | 10/26/06 | Bridon <i>et al.</i> | |
| | A22 2007/0207958 | 09/06/07 | Bridon <i>et al.</i> | |
| | A23 2007/0269863 | 11/22/07 | Bridon <i>et al.</i> | |
| | A24 5,840,733 | 11/24/98 | Krantz <i>et al.</i> | |
| | A25 5,843,440 | 12/01/98 | Pouletty <i>et al.</i> | |
| | A26 5,942,620 | 08/24/99 | Krantz <i>et al.</i> | |
| | A27 6,087,375 | 08/11/00 | Bridon <i>et al.</i> | |
| | A28 6,103,233 | 08/15/00 | Pouletty <i>et al.</i> | |
| | A29 6,277,583 | 08/21/01 | Krantz <i>et al.</i> | |

NY1-4069369v1

EXAMINER

/Brandon Fetterolf/

DATE CONSIDERED

08/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.F./

| | | |
|---|-------------------------|------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. | APPLICATION NO. |
| | 11767-032-999 | 09/623,543 |
| | APPLICANT | |
| | Bridon et al. | |
| | FILING DATE | ART UNIT |
| | September 5, 2000 | 1642 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | | Document Number | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|-----|-----------------|------------------|--|---|
| | A30 | 6,277,863 | 08/21/01 | Krantz <i>et al.</i> | |
| | A31 | 6,403,324 | 06/11/02 | Krantz <i>et al.</i> | |
| | A32 | 6,437,092 | 08/20/02 | Ezrin <i>et al.</i> | |
| | A33 | 6,440,417 | 08/27/02 | Thibaudeau <i>et al.</i> | |
| | A34 | 6,451,974 | 09/17/02 | Hansen | |
| | A35 | 6,602,981 | 08/05/03 | Ezrin <i>et al.</i> | |
| | A36 | 6,610,825 | 08/26/03 | Ezrin <i>et al.</i> | |
| | A37 | 6,706,892 | 03/16/04 | Ezrin <i>et al.</i> | |
| | A38 | 6,887,470 | 05/03/05 | Bridon <i>et al.</i> | |
| | A39 | 7,090,851 | 08/15/06 | Bridon <i>et al.</i> | |
| | A40 | 7,112,567 | 09/26/06 | Bridon <i>et al.</i> | |
| | A41 | 7,166,695 | 01/23/07 | Krantz <i>et al.</i> | |
| | A42 | 7,256,253 | 08/14/07 | Bridon <i>et al.</i> | |
| | A43 | 7,268,113 | 09/11/07 | Bridon <i>et al.</i> | |
| | A44 | 7,307,148 | 12/01/07 | Bousquet Gagnon <i>et al.</i> | |
| | A45 | 6,107,489 | 08/22/00 | Krantz <i>et al.</i> | |
| | A46 | 6,329,336 | 12/11/01 | Bridon <i>et al.</i> | |
| | A47 | 6,500,918 | 12/31/02 | Ezrin <i>et al.</i> | |
| | A48 | 2004/0127398 | 07/01/04 | Bridon <i>et al.</i> | |
| | A49 | 2004/0138100 | 07/15/04 | Bridon <i>et al.</i> | |
| | A50 | 09/424,571 | 11/22/99 | Ezrin <i>et al.</i> | |
| | A51 | 4,462,941 | 07/31/1984 | Lee <i>et al.</i> | |
| | A52 | 5,493,007 | 02/20/1996 | Burnier <i>et al.</i> | |
| | A53 | 5,580,853 | 12/03/1996 | Sytkowski | |
| | A54 | 5,654,276 | 08/05/1997 | Barrett <i>et al.</i> | |
| | A55 | 5,843,440 | 12/01/1998 | Pouletty <i>et al.</i> | |
| | A56 | 6,849,714 | 02/01/2005 | Bridon <i>et al.</i> | |
| | A57 | 6,514,500 | 02/04/2003 | Bridon <i>et al.</i> | |
| | A58 | 6,593,295 | 07/15/2003 | Bridon <i>et al.</i> | |

NY1-4069369v1

EXAMINER /Brandon Fetterolt/**DATE CONSIDERED** 08/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.F./

| | | |
|---|--|--------------------------------------|
| LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) | ATTY. DOCKET NO. 11767-032-999 | APPLICATION NO. 09/623,543 |
| | APPLICANT Bridon et al. | |
| | FILING DATE September 5, 2000 | ART UNIT 1642 |

U.S. PATENT DOCUMENTS

| *Examiner Initials | | Document Number | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----|-----------------|---------------|---|---|
| | A59 | 6,821,949 | 11/23/2004 | Bridon et al. | |
| | A60 | 6,329,336 | 12/11/2001 | Bridon et al. | |
| | A61 | 6,887,849 | 05/03/2005 | Bridon et al. | |

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | | Foreign Patent Document Country Code, Number, Kind Code (if known) | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|-----|--|---------------|---|---|---|
| | B01 | WO 00/69902 | 05/17/00 | ConjuChem, Inc. | | |
| | B02 | WO 00/69911 | 11/23/2000 | ConjuChem, Inc. | | |
| | B03 | WO 01/017568 | 09/07/00 | ConjuChem, Inc. | | |
| | B04 | WO 01/017614 | 09/07/00 | ConjuChem, Inc. | | |
| | B05 | WO 02/062844 | 01/02/02 | ConjuChem, Inc. | | |
| | B06 | WO 02/066511 | 02/15/02 | ConjuChem, Inc. | | |
| | B07 | WO 02/096935 | 05/31/02 | ConjuChem, Inc. | | |
| | B08 | WO 04/011498 | 07/29/03 | ConjuChem, Inc. | | |
| | B09 | WO 05/012346 | 07/26/04 | ConjuChem, Inc. | | |
| | B10 | WO 05/103087 | 04/22/05 | ConjuChem Biotechnologies Inc. | | |
| | B11 | WO 05/108418 | 06/15/05 | ConjuChem Biotechnologies Inc. | | |
| | B12 | WO 07/053946 | 11/09/06 | ConjuChem Biotechnologies Inc. | | |
| | B13 | WO 07/071068 | 12/22/06 | ConjuChem Biotechnologies Inc. | | |
| | B14 | WO 91/08220 | 06/13/91 | Houen Gunnar | | |
| | B15 | WO 97/25074 | 01/07/97 | Redcell Canada, Inc. | | |
| | B16 | WO 97/29372 | 01/07/97 | Redcell Inc. | | |
| | B17 | WO 97/46584 | 12/11/97 | Boehringer Mannheim GmbH | | |
| | B18 | WO 98/00171 | 06/30/97 | ConjuChem, Inc. | | |
| | B19 | WO 98/05351 | 02/12/98 | Amylin Pharmaceuticals, Inc. | | |
| | B20 | WO 98/11437 | 09/16/97 | ConjuChem, Inc. | | |
| | B21 | WO 99/07404 | 02/18/99 | Amylin Pharmaceuticals, Inc. | | |
| | B22 | WO 99/24071 | 05/20/99 | ConjuChem, Inc. | | |

NY1-4069369v1

| | |
|---|-----------------------------------|
| EXAMINER /Brandon Fetterolf/ | DATE CONSIDERED 08/15/2008 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.F./

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

11767-032-999

APPLICATION NO.

09/623,543

APPLICANT

Bridon et al.

FILING DATE

September 5, 2000

ART UNIT

1642

FOREIGN PATENT DOCUMENTS

| *Examiner Initials | | Foreign Patent Document Country Code, Number, Kind Code (if known) | Date mm/dd/yy | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T |
|--------------------|-----|--|---------------|---|---|---|
| | B23 | WO 99/24076 | 11/06/98 | ConjuChem, Inc. | | |
| | B24 | WO 99/24462 | 05/20/1999 | ConjuChem, Inc. | | |
| | B25 | WO 99/25727 | 05/27/99 | Amylin Pharmaceuticals, Inc. | | |
| | B26 | WO 99/25728 | 05/27/99 | Amylin Pharmaceuticals, Inc. | | |
| | B27 | WO 99/46283 | 09/16/99 | Zealand Pharmaceuticals A/S | | |

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T |
|--------------------|-----|--|---|
| | C01 | Alberts <i>et al.</i> , 1994, <i>Molecular Biology of the Cell</i> , Third Edition, New York: Garland Publishing, page G19. | |
| | C02 | Barragán <i>et al.</i> , 1996, "Interactions of Exendin(9-39) with the Effects of Glucagon-Like Peptide-1-(7-36) Amide and of Exendin-4 on Arterial Blood Pressure and Heart Rate in Rats," 67:63-68. | |
| | C03 | Binder <i>et al.</i> , 1984, "Insulin Pharmacokinetics," <i>Diabetes Care</i> 7:188-199. | |
| | C04 | Breton <i>et al.</i> , 1995, "Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin," <i>Eur. J. Biochem.</i> 231:563-569. | |
| | C05 | Catalog, <i>Shearwater Polymers, Inc., Functionalized Biocompatible Polymers for Research, Polyethylene Glycol Derivatives</i> , 1993. | |
| | C06 | Cooper, 1997, <i>The Cell A Molecular Approach</i> , ASM Press (Washington, DC), Sinauer Associates, Inc. (Sunderland, MA), 296-298, 648. | |
| | C07 | Edwards <i>et al.</i> , 1999 (December), "Glucagon-Like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans," <i>Diabetes</i> 48: 86-93. | |
| | C08 | Eng <i>et al.</i> , 1990, "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <i>J. Biol. Chem.</i> 265:20259-20262. | |
| | C09 | Eng <i>et al.</i> , 1992, "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom," <i>J. Biol. Chem.</i> 267:7402-7405. | |
| | C10 | Gennaro, ed., 1995, <i>Remington: The Science and Practice of Pharmacy</i> , 19 th Edition, 898, 931-94. | |
| | C11 | Göke <i>et al.</i> , 1989, "Characterization of the Receptor for Glucagon-like-peptide-1(7-36)amide on Plasma Membranes from Rat Insulinoma-derived Cells by Covalent Cross-Linking," <i>J. Mol. Endocrinol.</i> 2:93-98. | |
| | C12 | Göke <i>et al.</i> , 1992, "Solubilization of Active GLP-1 (7-36)amide Receptors From RINm5F Plasma Membranes," <i>FEBS Lett.</i> 300:232-236. | |
| | C13 | Göke <i>et al.</i> , 1993, "Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells," <i>J. Biol. Chem.</i> 268(26):19650-19655. | |
| | C14 | Göke <i>et al.</i> , 1995, "Distribution of GLP-1 Binding Sites in the Rat Brain: Evidence that Exendin-4 is a Ligand of Brain GLP-1 Binding Sites," <i>Eur. J. Neurosci.</i> 7:2294-2300. | |
| | C15 | Gombotz and Pettit, 1995, "Biodegradable Polymers for Protein and Peptide Drug Delivery," <i>Bioconjugate Chem.</i> 6:332-351. | |
| | C16 | Grand, 1989, "Acylation of Viral and Eukaryotic Proteins," <i>Biochem J.</i> 258:625-638. | |

NYI-4069369v1

EXAMINER /Brandon Fetterolf/**DATE CONSIDERED**

08/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.F./

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

11767-032-999

APPLICATION NO.

09/623,543

APPLICANT

Bridon et al.

FILING DATE

September 5, 2000

ART UNIT

1642

NON PATENT LITERATURE DOCUMENTS

| *Examiner Initials | | Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|-----|--|---|
| | C17 | Grieg et al., 1999 (January), "Once Daily Injection of Exendin-4 to Diabetic Mice Achieves Long-Term Beneficial Effects of Blood Glucose Concentrations," <i>Diabetologia</i> 42:45-50. | |
| | C18 | Harlow & Lane, 1988, <i>Antibodies: A Laboratory Manual</i> , pp. 101, 129. | |
| | C19 | Hoshino et al., 1984, "Primary Structure of Helodermin, a VIP-Secretin-Like Peptide Isolated from Gila Monster Venom," <i>FEBS Lett.</i> 178:233-239 | |
| | C20 | Isola et al., 1993, "A Potent Anti-Metastatic Activity of Tumor Invasion-Inhibiting Factor-2 and Albumin Conjugate," <i>Biochem. Biophys. Res. Comm.</i> 192:7-14. | |
| | C21 | Lewis, 1997, <i>Hawley's Condensed Chemical Dictionary, 13th Edition</i> , John Wiley & Sons, Inc. (New York), 487, 815. | |
| | C22 | Mattson et al., 1993, "A Practical Approach to Crosslinking," <i>Mol. Biol. Reports</i> 17:167-183. | |
| | C23 | Petrella et al., 1999 (May), "Development and Validation of an Immunoradiometric Assay (IRMA) for the Quantitation of Exendin-4 in Plasma and Its Application to Preclinical Toxicity and Phase I Clinical Evaluations," <i>Diabetes</i> 48:A425. | |
| | C24 | Poznansky & Juliano, 1984, "Biological Approaches to the Controlled Delivery of Drugs: A Critical Review," <i>Pharmacological Reviews</i> 36:277-335. | |
| | C25 | Raufman, 1996, "Bioactive Peptides from Lizard Venoms," <i>Regulatory Peptides</i> 61:1-18. | |
| | C26 | Richter et al., 1991, "Characterization of Glucagon-Like Peptide-1(7-36)amide Receptors of Rat Lung Membranes by Covalent Cross-Linking," <i>FEBS Lett.</i> 280:247-250 | |
| | C27 | Robberecht et al., 1985, "Immunoreactive Helodermin-like Peptides in Rat: A New Class of Mammalian Neuropeptides Related to Secretin and VIP," <i>Biochem Biophys. Res. Comm.</i> 130: 333-342. | |
| | C28 | Schirra et al., 1998, "Exendin(9-39)amide is an Antagonist of Glucagon-Like Peptide-1(7-36)amide in Humans," <i>J. Clin. Invest.</i> 101:1421-1430. | |
| | C29 | Schmidtdt et al., 1994, "Rat Parietal Cell Receptors for GLP-1-(7-36) Amide: Northern Blot, Cross-Linking, and Radioligand Binding," <i>Am. J. Physiol.</i> 267:G423-432. | |
| | C30 | Syed et al., 1997, "Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin," <i>Blood</i> 89:3243-3252. | |
| | C31 | Vandermeers et al., 1984, "Purification of a Novel Pancreatic Secretory Factor (PSF) and a Novel Peptide with VIP- and Secretin-like Properties (Helodermin) from Gila Monster Venom," <i>FEBS Lett.</i> 166:273-276. | |
| | C32 | Vandermeers et al., 1987, "Chemical, Immunological and Biological Properties of Peptides Like Vasoactive-Intestinal-Peptide and Peptide-Histidine-Isolucineamide Extracted from the Venom of Two Lizards (<i>Heloderma horridum</i> and <i>Heloderma suspectum</i>)," <i>Eur. J. Biochem.</i> 164:321-327. | |
| | C33 | Yeh et al., 1992, "Design of Yeast-Secreted Albumin derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," <i>Proc. Natl. Acad. Sci. USA</i> 89:1904-1908. | |
| | C34 | Meloun et al., 1975, "Complete Amino Acid Sequence of Human Serum Albumin," <i>FEBS Letters</i> 58, 134-137 | |
| | C35 | Davis et al., 1991, "Reduction of Immunogenicity and extension of circulating half-life of peptides and proteins," <i>Peptide and Protein Drug Delivery</i> , Marcel Dekker, Inc., NY, NY, 831-864 | |
| | C36 | Paige et al., 1995, "Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol," <i>Pharm. Research.</i> , Vol. 12(12), 1883-1888 | |
| | C37 | Poznansky, 1983, "Enzyme-protein conjugates: new possibilities for enzyme therapy," <i>Pharm. Ther.</i> , Vol. 21, pp. 53-76 | |
| | C38 | Poznansky et al., 1988, "Growth hormone-albumin conjugates reduced renal toxicity and altered plasma clearance," <i>Federation of European Biochemical Societies</i> , Vol. 239(1), pp 18-22 | |

NYI-4069369v1

EXAMINER

/Brandon Fetterolf/

DATE CONSIDERED

08/15/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.F./